Molecular therapy. Advances

Detailed study of stem cell strength and DNA damage in large-scale gene editing outside the body

Updated

Abstract

A framework for correcting Wiskott-Aldrich syndrome using a CRISPR-Cas9-AAV6 platform shows a largely favorable safety profile.

  • The platform enables large-scale manufacturing of hematopoietic stem and progenitor cells while maintaining their viability and functionality.
  • Fine-tuning AAV dosing and modulating the DNA damage response pathway led to improved correction and repopulation in living organisms.
  • A multi-tiered genotoxicity assessment revealed minimal off-target risks and no evidence of clonal dominance or transformation during the study.
  • Longitudinal monitoring showed rare off-target events and structural variants specific to the donor, underscoring the need for ongoing patient monitoring.
  • A specific chromosomal rearrangement was identified only after cell engraftment in mice, highlighting potential post-transplantation risks.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free